Steven Cohen Vaxcyte, Inc. Transaction History
Point72 Asset Management, L.P.
- $36.6 Billion
- Q3 2024
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 359,796 shares of PCVX stock, worth $29.2 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
359,796Holding current value
$29.2 Million% of portfolio
0.11%Shares
7 transactions
Others Institutions Holding PCVX
# of Institutions
355Shares Held
122MCall Options Held
775KPut Options Held
433K-
Vanguard Group Inc Valley Forge, PA11.4MShares$928 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X010.9MShares$886 Million0.67% of portfolio
-
Black Rock Inc. New York, NY9.94MShares$806 Million0.02% of portfolio
-
Ra Capital Management, L.P. Boston, MA8.69MShares$705 Million13.83% of portfolio
-
Capital Research Global Investors Los Angeles, CA4.9MShares$397 Million0.12% of portfolio
About Vaxcyte, Inc.
- Ticker PCVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,315,100
- Market Cap $4.81B
- Description
- Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...